Publications

  1. Kim E, Zucconi BE, Wu M, Nocco SE, Meyers DJ, McGee JS, Venkatesh S, Cohen DL, Gonzalez EC, Ryu B, Cole PA, Alani RM. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma. Cancer Res. 2019 May 15; 79(10):2649-2661.View Related Profiles. PMID: 30910803.
  2. Eisenstein A, Gonzalez EC, Raghunathan R, Xu X, Wu M, McLean EO, McGee J, Ryu B, Alani RM. Emerging Biomarkers in Cutaneous Melanoma. Mol Diagn Ther. 2018 04; 22(2):203-218.View Related Profiles. PMID: 29411301.
  3. Eisenstein A, Panova IP, Chung HJ, Goldberg LJ, Zhang Q, Lazova R, Bhawan J, Busam KJ, Symanowski JT, Alani RM, Ryu B. Quantitative assessment of neuropilin-2 as a simple and sensitive diagnostic assay for spitzoid melanocytic lesions. Melanoma Res. 2018 Feb; 28(1):71-75.View Related Profiles. PMID: 29227334.
  4. Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, Roy Burman SS, Fairall L, Milano C, Eroglu A, Proby CM, Dinkova-Kostova AT, Hancock WW, Gray JJ, Bradner JE, Valente S, Mai A, Anders NM, Rudek MA, Hu Y, Ryu B, Schwabe JWR, Mattevi A, Alani RM, Cole PA. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018 01 04; 9(1):53.View Related Profiles. PMID: 29302039.
  5. Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag. 2017 Mar; 4(1):13-37.View Related Profiles. PMID: 28758010.
  6. Hsu MY, Yang MH, Schnegg CI, Hwang S, Ryu B, Alani RM. Notch3 signaling-mediated melanoma-endothelial crosstalk regulates melanoma stem-like cell homeostasis and niche morphogenesis. Lab Invest. 2017 Jun; 97(6):725-736.View Related Profiles. PMID: 28165469; DOI: 10.1038/labinvest.2017.1;.
  7. Moriarty WF, Kim E, Gerber SA, Hammers H, Alani RM. Neuropilin-2 promotes melanoma growth and progression in vivo. Melanoma Res. 2016 Aug; 26(4):321-8.View Related Profiles. PMID: 26881875; DOI: 10.1097/CMR.0000000000000190;.
  8. Alani RM, Larson A, Falanga V. Paving a New Path Towards Academic Medicine-A Novel Approach to Graduate Medical Education in the United States. Acad Med. 2016 08; 91(8):1039-40.View Related Profiles. PMID: 27465087; DOI: 10.1097/ACM.0000000000001269;.
  9. Zhang C, Barrios MP, Alani RM, Cabodi M, Wong JY. A microfluidic Transwell to study chemotaxis. Exp Cell Res. 2016 Mar 15; 342(2):159-65. PMID: 26988422; DOI: 10.1016/j.yexcr.2016.03.010;.
  10. Zhang C, Shenk EM, Blaha LC, Ryu B, Alani RM, Cabodi M, Wong JY. A simple engineered platform reveals different modes of tumor-microenvironmental cell interaction. Biofabrication. 2016 Mar; 8(1):015001. PMID: 26716792; PMCID: PMC4854650; DOI: 10.1088/1758-5090/8/1/015001;.
  11. Alani RM, Cole PA, Yan G, Bowers EM. USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES. 2015.
  12. Rossi M, Tuck J, Kim OJ, Panova I, Symanowski JT, Mahalingam M, Riker AI, Alani RM, Ryu B. Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma. Br J Dermatol. 2014 Aug; 171(2):403-8.View Related Profiles. PMID: 24359286; DOI: 10.1111/bjd.12801;.
  13. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19; 6(224):224ra24. PMID: 24553385; PMCID: PMC4017867; DOI: 10.1126/scitranslmed.3007094;.
  14. Jay H. Kalin, Muzhou Wu, Dawn Hayward, Liqing Wang, Justin M. Roberts, Polina Prusevich, Wayne W. Hancock, James E. Bradner, Byungwoo Ryu, Rhoda M. Alani, Philip A. Cole. American Society of Biochemistry and Molecular Biology Annual Meeting. CoREST in Peace: Dual Action Inhibitors of Histone Deacetylase and LSD1 Demethylase. 2014.
  15. Laura Blaha, Chentian Zhang, Rhoda Alani, Mario Cabodi, and Joyce Wong. Biomedical Engineering Society, 2014 Annual Meeting. A Microfluidic Platform to Evaluate the Role of Vessel Permeability in Tumor Cell Extravasation. San Antonio. 2014.
  16. Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, Wang Y, Leslie NR, Xu GX, Widlund HR, Ryu B, Alani RM, Dutton-Regester K, Goding CR, Hayward NK, Wei W, Cui R. MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell. 2013 Aug 22; 51(4):409-22.View Related Profiles. PMID: 23973372; PMCID: PMC3792490; DOI: 10.1016/j.molcel.2013.08.010;.
  17. Howard JD, Moriarty WF, Park J, Riedy K, Panova IP, Chung CH, Suh KY, Levchenko A, Alani RM. Notch signaling mediates melanoma-endothelial cell communication and melanoma cell migration. Pigment Cell Melanoma Res. 2013 Sep; 26(5):697-707. PMID: 23773728; DOI: 10.1111/pcmr.12131;
  18. Ryu B, Hwang S, Alani RM. MicroRNAs as an emerging target for melanoma therapy. J Invest Dermatol. 2013 May; 133(5):1137-9.View Related Profiles. PMID: 23594536; DOI: 10.1038/jid.2012.505;.
  19. Yan G, Eller MS, Elm C, Larocca CA, Ryu B, Panova IP, Dancy BM, Bowers EM, Meyers D, Lareau L, Cole PA, Taverna SD, Alani RM. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J Invest Dermatol. 2013 Oct; 133(10):2444-52.View Related Profiles. PMID: 23698071; DOI: 10.1038/jid.2013.187;.
  20. Alani RM, Byungwoo R. BIOMARKERS FOR MELANOMA. 2012.